The European Union's medical regulator on Friday recommended the authorisation of the coronavirus vaccine jointly developed by AstraZeneca and Oxford University for all people aged 18 and above.

While the European Medicines Agency (EMA) said the shot is suitable for older people, member state Germany has advised against its use among the over-65s due to a lack of data, AFP reported.

Also Read | UN chief Antonio Guterres receives COVID-19 vaccine

"EMA has recommended granting a conditional marketing authorisation for COVID-19 Vaccine AstraZeneca to prevent coronavirus disease 2019 in people from 18 years of age," it said in a statement. 

The decision paves the way for a third vaccine to be approved for use across the 27-member bloc, after the ones developed by Pfizer-BioNTech and Moderna. 

The decision comes as Brussels and AstraZeneca remain locked in a dispute over supply issues, after the British-Swedish pharmaceutical company confirmed it will only be able to deliver a fraction of the doses it had initially promised to the EU in the short-term because of production problems.

That has come as a huge blow to Europe's already struggling rollout, while setting the EU on a collision course with former member Britain as they jostle for AstraZeneca's limited supplies.

In a sign of the growing tensions, the EU on Friday released a redacted version of its contract with AstraZeneca, while announcing a mechanism that could allow it to reject the export of vaccines made on European soil.

Also Read | US detects first cases of South African variant of COVID-19

Meanwhile, AstraZeneca has welcomed the EU decision to approve its vaccine. 

"Today's recommendation underscores the value of AstraZeneca's COVID-19 vaccine which is not only effective and well-tolerated, but also easy to administer," AstraZeneca boss Pascal Soriot said. 

The vaccine was developed in collaboration with researchers at the University of Oxford. 

The EMA decision to approve the vaccine was "an important milestone", Andrew Pollard, the director of the Oxford Vaccine group, said.